Terumo Corporation
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. It operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, int… Read more
Terumo Corporation (TRUMF) - Net Assets
Latest net assets as of December 2025: $1.52 Trillion USD
Based on the latest financial reports, Terumo Corporation (TRUMF) has net assets worth $1.52 Trillion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.26 Trillion) and total liabilities ($735.25 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.52 Trillion |
| % of Total Assets | 67.45% |
| Annual Growth Rate | 9.02% |
| 5-Year Change | 59.75% |
| 10-Year Change | 167.53% |
| Growth Volatility | 9.27 |
Terumo Corporation - Net Assets Trend (2001–2025)
This chart illustrates how Terumo Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Terumo Corporation (2001–2025)
The table below shows the annual net assets of Terumo Corporation from 2001 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $1.37 Trillion | +3.12% |
| 2024-03-31 | $1.33 Trillion | +19.44% |
| 2023-03-31 | $1.11 Trillion | +9.75% |
| 2022-03-31 | $1.01 Trillion | +18.17% |
| 2021-03-31 | $856.66 Billion | +13.48% |
| 2020-03-31 | $754.88 Billion | +8.13% |
| 2019-03-31 | $698.11 Billion | +26.83% |
| 2018-03-31 | $550.43 Billion | +12.44% |
| 2017-03-31 | $489.55 Billion | -4.30% |
| 2016-03-31 | $511.54 Billion | -10.81% |
| 2015-03-31 | $573.52 Billion | +15.57% |
| 2014-03-31 | $496.24 Billion | +13.32% |
| 2013-03-31 | $437.91 Billion | +24.22% |
| 2012-03-31 | $352.54 Billion | +5.09% |
| 2011-03-31 | $335.46 Billion | +5.78% |
| 2010-03-31 | $317.14 Billion | +14.01% |
| 2009-03-31 | $278.17 Billion | -3.73% |
| 2008-03-31 | $288.95 Billion | -0.10% |
| 2007-03-31 | $289.25 Billion | +5.81% |
| 2006-03-31 | $273.36 Billion | +24.29% |
| 2005-03-31 | $219.94 Billion | +12.73% |
| 2004-03-31 | $195.10 Billion | +5.73% |
| 2003-03-31 | $184.52 Billion | +2.56% |
| 2002-03-31 | $179.92 Billion | +4.41% |
| 2001-03-31 | $172.33 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Terumo Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1072.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.02 Trillion | 74.25% |
| Common Stock | $38.72 Billion | 2.83% |
| Other Comprehensive Income | $276.80 Billion | 20.23% |
| Other Components | $36.86 Billion | 2.69% |
| Total Equity | $1.37 Trillion | 100.00% |
Terumo Corporation Competitors by Market Cap
The table below lists competitors of Terumo Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PTC Inc
NASDAQ:PTC
|
$18.49 Billion |
|
Dupont De Nemours Inc
NYSE:DD
|
$18.50 Billion |
|
Skandinaviska Enskilda Banken AB A
PINK:SVKEF
|
$18.51 Billion |
|
CNVEF
PINK:CNVEF
|
$18.53 Billion |
|
Zimmer Biomet Holdings Inc
NYSE:ZBH
|
$18.45 Billion |
|
Alliant Energy Corp
NASDAQ:LNT
|
$18.41 Billion |
|
China Petroleum & Chemical Corporation
F:CHU
|
$18.38 Billion |
|
NVR Inc
NYSE:NVR
|
$18.35 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Terumo Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,327,090,000,000 to 1,368,535,000,000, a change of 41,445,000,000 (3.1%).
- Net income of 116,978,000,000 contributed positively to equity growth.
- Dividend payments of 35,622,000,000 reduced retained earnings.
- Share repurchases of 30,051,000,000 reduced equity.
- Other comprehensive income decreased equity by 17,579,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $116.98 Billion | +8.55% |
| Dividends Paid | $35.62 Billion | -2.6% |
| Share Repurchases | $30.05 Billion | -2.2% |
| Other Comprehensive Income | $-17.58 Billion | -1.28% |
| Other Changes | $7.72 Billion | +0.56% |
| Total Change | $- | 3.12% |
Book Value vs Market Value Analysis
This analysis compares Terumo Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-03-31 | $209.19 | $17.88 | x |
| 2002-03-31 | $218.40 | $17.88 | x |
| 2003-03-31 | $229.61 | $17.88 | x |
| 2004-03-31 | $244.34 | $17.88 | x |
| 2005-03-31 | $277.17 | $17.88 | x |
| 2006-03-31 | $336.54 | $17.88 | x |
| 2007-03-31 | $363.68 | $17.88 | x |
| 2008-03-31 | $366.62 | $17.88 | x |
| 2009-03-31 | $361.66 | $17.88 | x |
| 2010-03-31 | $417.23 | $17.88 | x |
| 2011-03-31 | $441.31 | $17.88 | x |
| 2012-03-31 | $463.81 | $17.88 | x |
| 2013-03-31 | $288.05 | $17.88 | x |
| 2014-03-31 | $326.69 | $17.88 | x |
| 2015-03-31 | $369.43 | $17.88 | x |
| 2016-03-31 | $646.58 | $17.88 | x |
| 2017-03-31 | $316.21 | $17.88 | x |
| 2018-03-31 | $363.84 | $17.88 | x |
| 2019-03-31 | $460.40 | $17.88 | x |
| 2020-03-31 | $498.54 | $17.88 | x |
| 2021-03-31 | $566.00 | $17.88 | x |
| 2022-03-31 | $668.93 | $17.88 | x |
| 2023-03-31 | $739.79 | $17.88 | x |
| 2024-03-31 | $891.64 | $17.88 | x |
| 2025-03-31 | $924.11 | $17.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Terumo Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.55%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.29%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.34x
- Recent ROE (8.55%) is below the historical average (10.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 9.66% | 9.45% | 0.63x | 1.63x | $-588.10 Million |
| 2002 | 8.03% | 0.01% | 657.20x | 1.58x | $-3.54 Billion |
| 2003 | 9.84% | 9.05% | 0.70x | 1.56x | $-291.30 Million |
| 2004 | 10.15% | 9.20% | 0.73x | 1.51x | $284.50 Million |
| 2005 | 12.34% | 11.80% | 0.74x | 1.42x | $5.15 Billion |
| 2006 | 11.88% | 13.14% | 0.70x | 1.30x | $5.13 Billion |
| 2007 | 12.88% | 13.47% | 0.75x | 1.27x | $8.31 Billion |
| 2008 | 15.02% | 14.16% | 0.75x | 1.42x | $14.50 Billion |
| 2009 | 13.26% | 12.18% | 0.80x | 1.36x | $9.07 Billion |
| 2010 | 12.85% | 12.89% | 0.74x | 1.34x | $9.03 Billion |
| 2011 | 9.65% | 9.85% | 0.78x | 1.25x | $-1.18 Billion |
| 2012 | 6.86% | 6.25% | 0.56x | 1.97x | $-11.06 Billion |
| 2013 | 10.74% | 11.69% | 0.52x | 1.76x | $3.26 Billion |
| 2014 | 6.87% | 7.30% | 0.56x | 1.68x | $-15.53 Billion |
| 2015 | 6.71% | 7.86% | 0.49x | 1.73x | $-18.88 Billion |
| 2016 | 9.91% | 9.65% | 0.58x | 1.76x | $-467.40 Million |
| 2017 | 11.24% | 10.70% | 0.50x | 2.09x | $6.06 Billion |
| 2018 | 16.59% | 15.53% | 0.54x | 1.96x | $36.26 Billion |
| 2019 | 11.38% | 13.26% | 0.53x | 1.61x | $9.67 Billion |
| 2020 | 11.29% | 13.55% | 0.51x | 1.64x | $9.73 Billion |
| 2021 | 9.02% | 12.59% | 0.45x | 1.58x | $-8.40 Billion |
| 2022 | 8.77% | 12.63% | 0.48x | 1.46x | $-12.42 Billion |
| 2023 | 8.04% | 10.89% | 0.51x | 1.44x | $-21.78 Billion |
| 2024 | 8.02% | 11.54% | 0.50x | 1.38x | $-26.34 Billion |
| 2025 | 8.55% | 11.29% | 0.57x | 1.34x | $-19.88 Billion |
Industry Comparison
This section compares Terumo Corporation's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,344,700,045
- Average return on equity (ROE) among peers: -67.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Terumo Corporation (TRUMF) | $1.52 Trillion | 9.66% | 0.48x | $18.47 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $520.03 Million | 8.62% | 0.25x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $121.35 Million | -35.38% | 0.57x | $16.24 Million |
| Alcon AG (ALC) | $18.82 Billion | -2.82% | 0.47x | $37.83 Billion |
| Align Technology Inc (ALGN) | $93.44 Million | 1.51% | 0.52x | $11.30 Billion |
| AngioDynamics Inc (ANGO) | $405.75 Million | 2.00% | 0.08x | $353.07 Million |
| Ansell Limited (ANSLF) | $1.40 Billion | 7.95% | 0.69x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.24 Billion |
| AtriCure Inc (ATRC) | $15.61 Million | -34.94% | 1.17x | $1.46 Billion |
| Avinger Inc (AVGR) | $-6.20 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $1.86 Million | -634.53% | 4.26x | $156.14 Million |